About InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Tocilizumab making it ideal for research use. This Tocilizumab biosimilar reacts with human IL-6 receptor also known as CD126. IL-6R is an 80 kDa type I cytokine receptor and a member of the immunoglobulin superfamily. IL-6R is expressed by activated T and B lymphocytes, monocytes, hepatocytes, and plasma cells. The IL-6 receptor α chain binds IL-6 but requires association with gp130 to initiate signal transduction. Upon IL-6 binding the IL-6R complex influences antigen-specific immune responses, inflammatory responses, neuronal development, and is a major mediator of the acute phase reaction. Tocilizumab binds to both soluble and membrane bound IL-6R and blocks the binding of IL-6 to IL-6R. InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar) Specifications IsotypeHuman IgG1 Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman IL-6R Reported ApplicationsFunctional assays ELISA FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A RRIDAB_2894735 Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
